Cytosolic Delivery of Tumor Antigens into Dendritic Cells
将肿瘤抗原胞质递送至树突状细胞
基本信息
- 批准号:9911314
- 负责人:
- 金额:$ 6.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-01-01 至 2022-12-31
- 项目状态:已结题
- 来源:
- 关键词:AllelesAnthrax diseaseAntigen Presentation PathwayAntigen-Presenting CellsAntigensBindingBinding ProteinsBiotechnologyCD8-Positive T-LymphocytesCancer VaccinesCell DeathCell surfaceCellsClinicCytosolDana-Farber Cancer InstituteDendritic CellsDevelopmentEngineeringEnvironmentEquipmentImmune responseImmune systemImmunotherapyIn VitroInstitutesLeadLightMalignant NeoplasmsMutationNaturePatientsPeptide FragmentsPeptidesPlayPolymersProcessProtein translocationProteinsResourcesRoleSystemT-Cell ActivationT-LymphocyteTissuesToxinTrainingTranslationsTumor AntigensVariantWorkanthrax lethal factoranti-cancerantibody engineeringanticancer researchbasecancer immunotherapycell typedesignimmune activationimmunogenicimprovedin vivonanoparticleneoantigensnon-Nativenovel strategiesnovel vaccinespeptide drugprotein aminoacid sequencesmall moleculetherapeutic proteintooltraffickingtumoruptakevaccine delivery
项目摘要
PROJECT SUMMARY/ABSTRACT
Cancer vaccines have recently emerged as a selective way to activate T cells against cancer. The treatments
are based on peptides, called tumor antigens, derived from peptide sequences in tumors that are immunogenic.
Another class of tumor antigens, called neoantigens, arise from mutations in tumors that have not been detected
by the immune system. These cancer vaccines with tumor antigens or neoantigens can promote antigen-specific,
rather than nonspecific, T-cell activation, by either generating new or amplifying existing immune responses
against tumors. Despite the promising anti-cancer immune responses observed with these treatments, effective
and selective activation of the immune system remains difficult.
Several challenges have limited the translation of cancer vaccines into the clinic: (1) Sufficient uptake of the
antigens by antigen presenting cells is difficult to achieve, which greatly influences whether the peptides are
processed or presented to T cells. (2) Proteasomal processing of the peptides is difficult to predict, which can
result in the formation of peptide fragments, other than the desired antigen, that neither bind to an HLA allele nor
activate an immune response. Antigen delivery systems can play crucial roles in improving cancer vaccines. The
delivery systems can perform two critical functions, which the absence of currently limits the efficacy of cancer
vaccines: promote targeting to dendritic cells (DCs) and facilitate cytosolic delivery.
This proposal describes the development of an anthrax delivery system for delivering tumor antigens. My
overarching hypothesis is that the anthrax machinery is well suited for delivering tumor antigens, because it
can efficiently perform protein translocation. In nature, the delivery system transports toxins into the cell cytosol
that rapidly induce cell death. The main components are easily modified for transporting non-native cargo into
cells, including therapeutic peptides, proteins, and even small molecules. This proposal will develop the
anthrax delivery system with two new features: to target dendritic cells and to deliver tumor antigens. These
features will be developed to enhance tumor antigen activity in vivo (Aim 1) and to shed light on antigen
processing and presentation (Aim 2). The impact of this work will extend beyond developing an effective tool
for tumor antigen delivery. It will also facilitate the identification and study of tumor antigens selective for T cell
activation, which will ultimately lead to the development of better tumor antigens for cancer vaccines in the
clinic and beyond.
The training plan and environment permits the design and study of the anthrax delivery system with the
Pentelute lab (MIT), Irvine lab (Koch Institute for Integrative Cancer Research at MIT), and Wu lab (Dana-
Farber Cancer Institute). The proposed studies will be performed with the equipment and resources available
in these labs, and with the facilities available at the Swanson Biotechnology Center at the Koch Institute.
项目总结/摘要
癌症疫苗最近出现作为一种选择性的方式来激活T细胞对抗癌症。的治疗
基于称为肿瘤抗原的肽,其来源于具有免疫原性的肿瘤中的肽序列。
另一类肿瘤抗原,称为新抗原,产生于尚未检测到的肿瘤突变
免疫系统的影响。这些具有肿瘤抗原或新抗原的癌症疫苗可以促进抗原特异性,
而不是非特异性的T细胞激活,通过产生新的或放大现有的免疫反应,
对抗肿瘤尽管用这些治疗观察到有希望的抗癌免疫应答,但有效的免疫抑制剂仍然存在。
免疫系统的选择性激活仍然很困难。
几个挑战限制了癌症疫苗向临床的转化:(1)足够的肿瘤疫苗的摄取。
很难通过抗原呈递细胞获得抗原,这极大地影响了肽是否被
处理或呈递给T细胞。(2)蛋白酶体对肽的加工是难以预测的,这可以
导致形成除了所需抗原以外的肽片段,其既不结合HLA等位基因,
激活免疫反应抗原递送系统可以在改进癌症疫苗中发挥关键作用。的
递送系统可以执行两个关键功能,目前缺乏这两个功能限制了癌症的疗效。
疫苗:促进靶向树突状细胞(DC)并促进胞质递送。
该提案描述了用于递送肿瘤抗原的炭疽递送系统的开发。我
最重要的假设是,炭疽机器非常适合于传递肿瘤抗原,因为它
能高效地进行蛋白质转位。在自然界中,传递系统将毒素转运到细胞胞质溶胶中
快速诱导细胞死亡主要部件很容易修改,用于将非本地货物运输到
细胞,包括治疗肽,蛋白质,甚至小分子。该提案将发展
炭疽传递系统具有两个新的特点:靶向树突状细胞和传递肿瘤抗原。这些
将开发特征以增强体内肿瘤抗原活性(目标1)并阐明抗原
处理和呈现(目标2)。这项工作的影响将超越开发一个有效的工具
用于肿瘤抗原递送。这也将有助于T细胞选择性肿瘤抗原的鉴定和研究
激活,这将最终导致开发更好的肿瘤抗原用于癌症疫苗,
诊所和超越
培训计划和环境允许设计和研究炭疽传播系统,
Pentelute实验室(MIT)、Irvine实验室(MIT科赫综合癌症研究所)和Wu实验室(Dana-
Farber癌症研究所)。拟议的研究将利用现有的设备和资源进行
在这些实验室,并与设施可在斯旺森生物技术中心在科赫研究所。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nicholas L Truex其他文献
Nicholas L Truex的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nicholas L Truex', 18)}}的其他基金
Cytosolic Delivery of Tumor Antigens into Dendritic Cells
将肿瘤抗原胞质递送至树突状细胞
- 批准号:
10297830 - 财政年份:2020
- 资助金额:
$ 6.49万 - 项目类别:
相似海外基金
The Importance and Function of Heme Degrading Enzymes during Anthrax Disease
炭疽病期间血红素降解酶的重要性和功能
- 批准号:
9323699 - 财政年份:2017
- 资助金额:
$ 6.49万 - 项目类别:
Edema Toxin Suppression of Immune Responses During Anthrax Disease
炭疽病期间水肿毒素抑制免疫反应
- 批准号:
7695606 - 财政年份:2009
- 资助金额:
$ 6.49万 - 项目类别:
Edema Toxin Suppression of Immune Responses During Anthrax Disease
炭疽病期间水肿毒素抑制免疫反应
- 批准号:
8716418 - 财政年份:
- 资助金额:
$ 6.49万 - 项目类别:
Edema Toxin Suppression of Immune Responses During Anthrax Disease
炭疽病期间水肿毒素抑制免疫反应
- 批准号:
8379006 - 财政年份:
- 资助金额:
$ 6.49万 - 项目类别:
Edema Toxin Suppression of Immune Responses During Anthrax Disease
炭疽病期间水肿毒素抑制免疫反应
- 批准号:
8137849 - 财政年份:
- 资助金额:
$ 6.49万 - 项目类别:
Edema Toxin Suppression of Immune Responses During Anthrax Disease
炭疽病期间水肿毒素抑制免疫反应
- 批准号:
8320309 - 财政年份:
- 资助金额:
$ 6.49万 - 项目类别: